Date: 2018-01-04

Type of information: Licensing agreement

Compound: F17727

Company: Pierre Fabre (France) Boston Pharmaceuticals (USA - MA)

Therapeutic area: Cardiovascular diseases

Type agreement: licensing

Action mechanism: potassium channel blocker

Disease: atrial fibrillation


  • • On January 4, 2018, Pierre Fabre and Boston Pharmaceuticals announced they have entered into a worldwide licensing agreement for Pierre Fabre's selective potassium channel blocker, F17727. F17727 is a small molecule in late preclinical development for the potential treatment of atrial fibrillation. Under the terms of the agreement, Pierre Fabre grants Boston Pharmaceuticals worldwide exclusive rights for the development, manufacturing and commercialization of F17727.

Financial terms:

  • Financial terms of the agreement were not disclosed.

Latest news:

Is general: Yes